Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-02-01
2011-02-01
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S616000
Reexamination Certificate
active
07879865
ABSTRACT:
The present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase. In particular embodiments, the CNS disease is a neurodegenerative disease. In further embodiments, the neurogenerative disease is an inherited neurodegenerative disease, such as those inherited neurodegenerative diseases which are polyglutamine expansion diseases. The individual can be a mammal such as a primate or human.
REFERENCES:
patent: 4690918 (1987-09-01), Beppu et al.
patent: 5055608 (1991-10-01), Marks et al.
patent: 5175191 (1992-12-01), Marks et al.
patent: 5330744 (1994-07-01), Pontremoli et al.
patent: 5369108 (1994-11-01), Breslow et al.
patent: 5608108 (1997-03-01), Marks et al.
patent: 5654333 (1997-08-01), Samid
patent: 5668179 (1997-09-01), Breslow et al.
patent: 5700811 (1997-12-01), Breslow et al.
patent: 5773474 (1998-06-01), Breslow et al.
patent: 5840960 (1998-11-01), Marks et al.
patent: 5932616 (1999-08-01), Breslow et al.
patent: 6087367 (2000-07-01), Breslow et al.
patent: 6231880 (2001-05-01), Perrine
patent: 6239176 (2001-05-01), Nudelman et al.
patent: 6262116 (2001-07-01), Pandolfi et al.
patent: 6451334 (2002-09-01), Perrine
patent: 6495719 (2002-12-01), Lan-Hargest et al.
patent: 6511990 (2003-01-01), Breslow et al.
patent: 6656905 (2003-12-01), Mori et al.
patent: RE38506 (2004-04-01), Breslow et al.
patent: 6905669 (2005-06-01), DiMartino
patent: 6905699 (2005-06-01), Nakamura
patent: 7126001 (2006-10-01), Breslow et al.
patent: 7148257 (2006-12-01), Bacopoulos et al.
patent: 7199134 (2007-04-01), Breslow et al.
patent: 2002/0061860 (2002-05-01), Li et al.
patent: 2002/0065282 (2002-05-01), Georges et al.
patent: 2002/0103192 (2002-08-01), Curtin et al.
patent: 2003/0082666 (2003-05-01), Kammer et al.
patent: 2003/0114525 (2003-06-01), Kammer et al.
patent: 2003/0161830 (2003-08-01), Jackson et al.
patent: 2003/0235588 (2003-12-01), Richon et al.
patent: 2004/0018968 (2004-01-01), Sgouros et al.
patent: 2004/0072735 (2004-04-01), Richon et al.
patent: 2004/0077591 (2004-04-01), Dangond
patent: 2004/0087657 (2004-05-01), Richon et al.
patent: 2004/0122101 (2004-06-01), Miller et al.
patent: 2004/0127522 (2004-07-01), Chiao et al.
patent: 2004/0127523 (2004-07-01), Bacopoulos et al.
patent: 2004/0132643 (2004-07-01), Fojo et al.
patent: 2004/0132825 (2004-07-01), Richon et al.
patent: 2004/0142859 (2004-07-01), Steffan et al.
patent: 2004/0167184 (2004-08-01), Wiech et al.
patent: 2005/0004007 (2005-01-01), Grant et al.
patent: 2006/0009526 (2006-01-01), Richon et al.
patent: 2006/0009527 (2006-01-01), Richon et al.
patent: 2006/0167103 (2006-07-01), Bacopoulos et al.
patent: 2006/0276547 (2006-12-01), Bacopoulos et al.
patent: 2007/0060614 (2007-03-01), Bacopoulos et al.
patent: 2007/0190022 (2007-08-01), Bacopoulos et al.
patent: 2008/0119562 (2008-05-01), Richon et al.
patent: 2008/0227862 (2008-09-01), Richon et al.
patent: 2008/0249179 (2008-10-01), Miller et al.
patent: 0931792 (1999-07-01), None
patent: 1123111 (2001-08-01), None
patent: 1170008 (2002-01-01), None
patent: 1174438 (2002-01-01), None
patent: 0547000 (2003-06-01), None
patent: 2 309 696 (1997-06-01), None
patent: 7-196686 (1995-08-01), None
patent: 11-302173 (1999-11-01), None
patent: 11-335375 (1999-12-01), None
patent: 2000-256194 (2000-09-01), None
patent: 2001/348340 (2001-12-01), None
patent: 2001-354694 (2001-12-01), None
patent: WO 90/09092 (1990-08-01), None
patent: WO 93/07148 (1993-04-01), None
patent: WO 95/31977 (1995-11-01), None
patent: WO 97/11366 (1997-03-01), None
patent: WO 97/35990 (1997-10-01), None
patent: WO 98/39965 (1998-09-01), None
patent: WO 98/40080 (1998-09-01), None
patent: WO 98/55449 (1998-12-01), None
patent: WO 00/08048 (2000-02-01), None
patent: WO 00/21979 (2000-04-01), None
patent: WO 00/71703 (2000-11-01), None
patent: WO 01/14581 (2001-03-01), None
patent: WO 01/16106 (2001-03-01), None
patent: WO 01/18045 (2001-03-01), None
patent: WO 01/18171 (2001-03-01), None
patent: WO 0118171 (2001-03-01), None
patent: WO 01/38322 (2001-05-01), None
patent: WO 01/42437 (2001-06-01), None
patent: WO 01/70675 (2001-09-01), None
patent: WO 02/07722 (2002-01-01), None
patent: WO 02/15921 (2002-02-01), None
patent: WO 02/22577 (2002-03-01), None
patent: WO 02/26696 (2002-04-01), None
patent: WO 02/26703 (2002-04-01), None
patent: WO 02/30879 (2002-04-01), None
patent: WO 02/46129 (2002-06-01), None
patent: WO 02/46144 (2002-06-01), None
patent: WO 02/50285 (2002-06-01), None
patent: WO 02/051842 (2002-07-01), None
patent: WO 02/055017 (2002-07-01), None
patent: WO 02/085400 (2002-10-01), None
patent: WO 02/090534 (2002-11-01), None
patent: WO 03/083067 (2003-10-01), None
patent: WO 2005/023179 (2005-03-01), None
Http://www.oncologychannel.com/braincanceer/types.shtml (2007).
Furamai et al. (2001).Proc. Natl. Acad. Sci. USA 98: 87-92.
International Search Report for PCT/US02/33246, mailed Jul. 22, 2003.
Komatsu et al. (2001).Cancer Res. 61: 4459-4466.
Lee et al. (2001).Cancer Res. 61: 931-934.
Saito et al. (1999).Proc. Natl. Acad. Sci. USA 96: 4592-4597.
Su et al. (2000).Cancer Res. 60: 3137-3142.
Suzuki et al. (1999).J. Med. Chem. 42: 3001-3003.
Yoshida (1995).Bioessays 17: 423-430.
Arky et al., Physician's Desk Reference, Ed. 51:2198-2201, 1997.
Bates et al., “Polyglutamine Expansion and Huntington's Disease,” Biochemical Society Transactions, 1998, vol. 26, No. 3, pp. 471-475.
Bates et al., “Symposium: Transgenic Models Of Neurodegeneration; Transgenic Mice In The Study Of Polyglutamine Repeat Expansion Diseases”, Brain Pathology, vol. 8, 1998, pp. 699-714.
Bates et al., Transgenic Models of Huntington's Disease, Human Molecular Genetics, 1997, vol. 6, No. 10, Rev. Issue, pp. 1633-1637.
Butler et al., “Suberoylanilide Hydroxamic Acid, An Inhibitor Of Histone Deacetylase, Suppresses The Growth Of Prostate Cancer Cells In Vitro And In Vivo”, Cancer Research, vol. 60, Sep. 15, 2000, pp. 5165-5170.
Cattaneo et al., “Loss Of Normal Huntingtin Function: New Developments In Huntington's Disease Research”, Trends in Neurosciences, vol. 24, No. 3, Mar. 2001, pp. 182-188.
Cha, J., “Transcriptional Dysregulation In Huntington's Disease”, TINS, vol. 23, No. 9, 2000, pp. 387-392.
Davies et al., “Formation Of Neuronal Intranuclear Inclusions Underlies The Neurological Dysfunction In Mice Transgenic For The HD Mutation”, Cell, vol. 90, Aug. 8, 1997, pp. 537-548.
Difiglia et al., “Aggregation Of Huntingtin In Neuronal Intranuclear Inclusions And Dystrophic Neurites In Brain”, Science, vol. 277, Sep. 26, 1997, pp. 1990-1993.
Dunah et al., “Spl and TAFII130 Transcriptional Activity Disrupted In Early Huntington's Disease”, Science, vol. 296, Jun. 21, 2002, pp. 2238-2243.
Ferrante et al., “Neuroprotective Effects Of Creatine In A Transgenic Mouse Model Of Huntington's Disease”, The Journal of Neuroscience, vol. 20, No. 12, Jun. 15, 2000, pp. 4389-4397.
Furumai et al., “FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases,” Cancer Res., 62(17):4916-4921, 2002.
Gottlicher et al., “Valporic Acid Defines a Novel Class of HDAC Inhibitors Inducing Differentiation of Transformed Cells,” The EMBO Journal, 2002, vol. 20, No. 24, pp. 6969-6978.
Gupta et al., “Characterization of a Phylotoxic Cyclotetrapeptide, a Novel Chiamydocin Analog, from Verticillum Coccosporum,” (1994) Tetrahedron Letters, 35(33), 6009-6012.
Gurney, “The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies,” J. Neurol. Sci., 152(Suppl. I):S67-S73, 1997.
Gutekunst et al., “Nuclear And Neuropil Aggregates In Huntington's Disease: Relationship To Neuropathology”, The Journal of Neuroscience, vol. 19, No. 7, Apr. 1, 1999, pp. 2522-2534.
Han et al., “Apicidin, a histone deacetylase inhibitor, inhibits p
Marks Paul A.
Richon Victoria M.
Rifkind Richard A.
Elrifi, Esq. Ivor R.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Sloan-Kettering Institute for Cancer Research
Weddington Kevin
LandOfFree
Treatment of cancer of the brain using histone deacetylase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of cancer of the brain using histone deacetylase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cancer of the brain using histone deacetylase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2624992